Date: 2013-07-30
Type of information: Commercialisation agreement
Compound: ConfirmMDx™ for prostate cancer test
Company: MDX Health (Belgium) - Three Rivers Provider Network (TRPN) (USA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On July 30, 2013, MDxHealth, a belgian molecular diagnostic company that develops and commercializes epigenetic tests to support the diagnosis and treatment of cancer patients, has announced that it has entered into agreements with Three Rivers Provider Network (TRPN). The agreement provides expanded access to the company\'s ConfirmMDx for Prostate Cancer test to the networks\' combined 10 million covered lives within the United States.
Three Rivers Provider Network, Inc. (TRPN) is a Preferred Provider Organizations (PPO) in the U.S. The TRPN network is now comprised of more than 600,000 total providers, including more than 5,000 hospitals and 70,000 ancillary facilities. Through its clients, approximately 10 million lives now have access to the TRPN PPO network.
Financial terms:
Latest news:
